BMY

SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 12

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,974

Underlying: Common Stock, $0.10 par value · 6,974 shares

Expires 2024-02-03

F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 11

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,440

Underlying: Common Stock, $0.10 par value · 7,440 shares

Expires 2023-12-02

F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 10

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,975

Underlying: Common Stock, $0.10 par value · 6,975 shares

Expires 2023-10-28

F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 9

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,975

Underlying: Common Stock, $0.10 par value · 6,975 shares

Expires 2023-07-29

F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 8

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,974

Underlying: Common Stock, $0.10 par value · 6,974 shares

Expires 2023-04-29

F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 7

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,463

Underlying: Common Stock, $0.10 par value · 10,463 shares

Expires 2023-01-28

F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 6

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,740

Underlying: Common Stock, $0.10 par value · 16,740 shares

Expires 2022-12-17

F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 5

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,464

Underlying: Common Stock, $0.10 par value · 10,464 shares

Expires 2022-10-31

F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 4

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,460

Underlying: Common Stock, $0.10 par value · 10,460 shares

Expires 2022-04-30

F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 3

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,255

Underlying: Common Stock, $0.10 par value · 3,255 shares

Expires 2022-01-30

F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · nonDerivative · entry 2

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Indirect · 401(k)

Disclosed balance after: 1,966

F3 · shares: Based on a plan statement as of the end of the most recent fiscal quarter.

SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · nonDerivative · entry 1

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,819

F1 · shares: On November 20, 2019 ("Closing Date"), Bristol-Myers Squibb Company ("BMS") completed the previously announced acquisition of Celgene Corporation ("Celgene") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), and Celgene. Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the "Merger"). The transactions on this form were not reported in a timely manner due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person.

F2 · shares: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee.

SEC source: 0000014272-19-000213 · wf-form4_157489387998406.xml · derivative · entry 6

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,182

Underlying: Common Stock, $0.10 par value · 33,182 shares

Expires 2022-03-01

F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F4 · derivative.exercise_price: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award.

F9 · derivative.exercise_price: The restricted stock unit vests in full on March 1, 2022, which is the end of the original performance period associated with the original Performance Share Unit award.

F1 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F4 · derivative.exercise_date: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award.

F9 · derivative.exercise_date: The restricted stock unit vests in full on March 1, 2022, which is the end of the original performance period associated with the original Performance Share Unit award.

SEC source: 0000014272-19-000213 · wf-form4_157489387998406.xml · derivative · entry 5

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,614

Underlying: Common Stock, $0.10 par value · 51,614 shares

Expires 2022-03-01

F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F8 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on March 1, 2020.

F1 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F8 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 1, 2020.

SEC source: 0000014272-19-000213 · wf-form4_157489387998406.xml · derivative · entry 4

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,228

Underlying: Common Stock, $0.10 par value · 6,228 shares

Expires 2022-02-04

F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F7 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on February 4, 2020.

F1 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F7 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on February 4, 2020.

SEC source: 0000014272-19-000213 · wf-form4_157489387998406.xml · derivative · entry 3

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,965

Underlying: Common Stock, $0.10 par value · 9,965 shares

Expires 2021-05-08

F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on May 8, 2019.

F1 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on May 8, 2019.

SEC source: 0000014272-19-000213 · wf-form4_157489387998406.xml · derivative · entry 2

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,945

Underlying: Common Stock, $0.10 par value · 14,945 shares

Expires 2021-03-01

F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F4 · derivative.exercise_price: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award.

F5 · derivative.exercise_price: The restricted stock unit vests in full on March 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award.

F1 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F4 · derivative.exercise_date: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award.

F5 · derivative.exercise_date: The restricted stock unit vests in full on March 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award.

SEC source: 0000014272-19-000213 · wf-form4_157489387998406.xml · derivative · entry 1

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,650

Underlying: Common Stock, $0.10 par value · 4,650 shares

Expires 2020-10-30

F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F2 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on October 30, 2018.

F3 · date: On November 20, 2019 ("Closing Date"), Bristol-Myers Squibb Company ("BMS") completed the previously announced acquisition of Celgene Corporation ("Celgene") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), and Celgene. Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the "Merger"). The transactions on this form were not reported in a timely manner due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person.

F1 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F2 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on October 30, 2018.

SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 10

BONNEY MICHAEL W · CIK 0001219016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,847

Underlying: Common Stock, $0.10 par value · 8,847 shares

Expires 2022-06-03

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F8 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on June 3, 2020.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F8 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on June 3, 2020.

SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 9

BONNEY MICHAEL W · CIK 0001219016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,805

Underlying: Common Stock, $0.10 par value · 1,805 shares

Expires 2021-06-13

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F7 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on June 13, 2019.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F7 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on June 13, 2019.

SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 8

BONNEY MICHAEL W · CIK 0001219016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 558

Underlying: Common Stock, $0.10 par value · 558 shares

Expires 2020-06-14

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on June 14, 2018.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on June 14, 2018.

SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 7

BONNEY MICHAEL W · CIK 0001219016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,674

Underlying: Common Stock, $0.10 par value · 24,674 shares

Expires 2028-06-13

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 6

BONNEY MICHAEL W · CIK 0001219016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,635

Underlying: Common Stock, $0.10 par value · 19,635 shares

Expires 2027-06-14

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 5

BONNEY MICHAEL W · CIK 0001219016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,460

Underlying: Common Stock, $0.10 par value · 20,460 shares

Expires 2026-06-15

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 4

BONNEY MICHAEL W · CIK 0001219016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock, $0.10 par value · 18,700 shares

Expires 2025-06-17

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 3

BONNEY MICHAEL W · CIK 0001219016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock, $0.10 par value · 18,700 shares

Expires 2025-04-14

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · nonDerivative · entry 2

BONNEY MICHAEL W · CIK 0001219016 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 2,000

SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · nonDerivative · entry 1

BONNEY MICHAEL W · CIK 0001219016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,069

F1 · shares: On November 20, 2019 ("Closing Date"), Bristol-Myers Squibb Company ("BMS") completed the previously announced acquisition of Celgene Corporation ("Celgene") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), and Celgene. Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the "Merger"). Due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person, this Form 4 is being amended to report the correct number of securities beneficially owned by the Reporting Person.

F2 · shares: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee.

F3 · shares: Includes settlement of 1860 deferred share units that were paid out in connection with the Merger.

SEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · derivative · entry 8

Haller Julia A · CIK 0001656082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,847

Underlying: Common Stock, $0.10 par value · 8,847 shares

Expires 2022-06-03

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F8 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on June 3, 2020.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F8 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on June 3, 2020.

SEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · derivative · entry 7

Haller Julia A · CIK 0001656082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,805

Underlying: Common Stock, $0.10 par value · 1,805 shares

Expires 2021-06-13

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F7 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on June 13, 2019.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F7 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on June 13, 2019.

SEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · derivative · entry 6

Haller Julia A · CIK 0001656082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 558

Underlying: Common Stock, $0.10 par value · 558 shares

Expires 2020-06-14

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on June 14, 2018.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on June 14, 2018.

SEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · derivative · entry 5

Haller Julia A · CIK 0001656082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,674

Underlying: Common Stock, $0.10 par value · 24,674 shares

Expires 2028-06-13

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · derivative · entry 4

Haller Julia A · CIK 0001656082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,635

Underlying: Common Stock, $0.10 par value · 19,635 shares

Expires 2027-06-14

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · derivative · entry 3

Haller Julia A · CIK 0001656082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,460

Underlying: Common Stock, $0.10 par value · 20,460 shares

Expires 2026-06-15

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · derivative · entry 2

Haller Julia A · CIK 0001656082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock, $0.10 par value · 18,700 shares

Expires 2025-10-15

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · nonDerivative · entry 1

Haller Julia A · CIK 0001656082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,409

F1 · shares: Total includes 200 shares held jointly with spouse in a brokerage account.

F2 · shares: On November 20, 2019 ("Closing Date"), Bristol-Myers Squibb Company ("BMS") completed the previously announced acquisition of Celgene Corporation ("Celgene") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), and Celgene. Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the "Merger"). Due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person, this Form 4 is being amended to report the correct number of securities beneficially owned by the Reporting Person.

F3 · shares: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 26

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,028

Underlying: Common Stock, $0.10 par value · 45,028 shares

Expires 2022-03-01

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_price: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award.

F14 · derivative.exercise_price: The restricted stock unit vests in full on March 1, 2022, which is the end of the original performance period associated with the original Performance Share Unit award.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_date: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award.

F14 · derivative.exercise_date: The restricted stock unit vests in full on March 1, 2022, which is the end of the original performance period associated with the original Performance Share Unit award.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 25

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,048

Underlying: Common Stock, $0.10 par value · 70,048 shares

Expires 2022-03-01

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F13 · derivative.exercise_price: The restricted stock unit vests in three equal installments beginning on March 1, 2020.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F13 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on March 1, 2020.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 24

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,777

Underlying: Common Stock, $0.10 par value · 10,777 shares

Expires 2022-02-04

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F12 · derivative.exercise_price: The restricted stock unit vests in three equal installments beginning on February 4, 2020.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F12 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on February 4, 2020.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 23

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,245

Underlying: Common Stock, $0.10 par value · 17,245 shares

Expires 2021-05-08

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F11 · derivative.exercise_price: The restricted stock unit vests in three equal installments beginning on May 8, 2019.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F11 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on May 8, 2019.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 22

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,865

Underlying: Common Stock, $0.10 par value · 25,865 shares

Expires 2021-03-01

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_price: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award.

F10 · derivative.exercise_price: The restricted stock unit vests in full on March 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_date: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award.

F10 · derivative.exercise_date: The restricted stock unit vests in full on March 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 21

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,804

Underlying: Common Stock, $0.10 par value · 5,804 shares

Expires 2020-10-30

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F9 · derivative.exercise_price: The restricted stock unit vests in three equal installments beginning on October 30, 2018.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F9 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on October 30, 2018.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 20

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,707

Underlying: Common Stock, $0.10 par value · 10,707 shares

Expires 2020-05-01

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F8 · derivative.exercise_price: The restricted stock unit vests in three equal installments beginning on May 1, 2018.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F8 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on May 1, 2018.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 19

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,059

Underlying: Common Stock, $0.10 par value · 16,059 shares

Expires 2020-03-01

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_price: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award.

F7 · derivative.exercise_price: The restricted stock unit vests in full on March 1, 2020, which is the end of the original performance period associated with the original Performance Share Unit award.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_date: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award.

F7 · derivative.exercise_date: The restricted stock unit vests in full on March 1, 2020, which is the end of the original performance period associated with the original Performance Share Unit award.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 18

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,957

Underlying: Common Stock, $0.10 par value · 33,957 shares

Expires 2028-10-29

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 17

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,958

Underlying: Common Stock, $0.10 par value · 33,958 shares

Expires 2028-07-30

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 16

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,958

Underlying: Common Stock, $0.10 par value · 33,958 shares

Expires 2028-05-08

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 15

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,173

Underlying: Common Stock, $0.10 par value · 21,173 shares

Expires 2028-01-29

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 14

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,932

Underlying: Common Stock, $0.10 par value · 48,932 shares

Expires 2027-10-30

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 13

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,288

Underlying: Common Stock, $0.10 par value · 21,288 shares

Expires 2027-07-31

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.